AstraZeneca and MedImmune, its global biologics research and development arm, today announced final overall survival (OS) results for a late-stage trial using a combination of Imfinzi and tremelimumab, an anti-CTLA4 antibody, did not support further study in some patients with advanced lung cancer
Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer, said: “We are encouraged to see that Imfinzi monotherapy activity is in-line with that of the anti-PD-1 class in previously-untreated patients with Stage IV non-small cell lung cancer; however, we are disappointed that these results missed the statistical significance. We remain confident in Imfinzi as the cornerstone of our IO programme and continue to evaluate its potential in ongoing non-small cell lung cancer trials, including Imfinzi and Imfinzi plus tremelimumab in combination with chemotherapy.”
Imfinzi is approved for unresectable, Stage III nonsmall cell lung cancer in more than 40 countries, including the US, EU, and Japan Imfinzi is currently being tested in a range of Phase III trials for Stage IV nonsmall cell lung cancer.
